Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 10, Issue 1, Pages 212
Publisher
Springer Nature
Online
2012-10-23
DOI
10.1186/1479-5876-10-212
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
- (2011) Angelo Di Leo et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome profiling of ERBB2-amplified breast cancers
- (2010) Fabrice Sircoulomb et al. BMC CANCER
- Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples
- (2010) Anna Żaczek et al. CLINICAL BIOCHEMISTRY
- Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
- (2010) John MS Bartlett et al. LANCET ONCOLOGY
- Fifteen-year trends in metastatic breast cancer survival in Greece
- (2009) U. Dafni et al. BREAST CANCER RESEARCH AND TREATMENT
- RNA Extraction from Archival Formalin-Fixed Paraffin-Embedded Tissue: A Comparison of Manual, Semiautomated, and Fully Automated Purification Methods
- (2009) K. Bohmann et al. CLINICAL CHEMISTRY
- Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers
- (2009) D. J. Slamon et al. JNCI-Journal of the National Cancer Institute
- Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
- (2009) C. Oakman et al. JNCI-Journal of the National Cancer Institute
- Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
- (2009) F. P. O'Malley et al. JNCI-Journal of the National Cancer Institute
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Aberrations of ERBB2 and TOP2A genes in breast cancer
- (2009) Kirsten Vang Nielsen et al. Molecular Oncology
- Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
- (2009) Christos Christodoulou et al. ONCOLOGY
- The value ofTOP2Agene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D
- (2008) Kirsten Vang Nielsen et al. ACTA ONCOLOGICA
- Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation
- (2008) George Fountzilas et al. CANCER INVESTIGATION
- Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
- (2008) Edurne Arriola et al. LABORATORY INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More